Biohaven
NEWS
Pfizer made the splash of the young week Tuesday morning, inking an acquisition deal with New Haven, Connecticut-based Biohaven Pharma totaling $11.6 billion.
Since its $63 billion acquisition of Allergan in 2019, AbbVie has become one of the leading companies developing therapies for migraine.
The American Academy of Neurology Annual Meeting (AAN) was held virtually and in-person in Seattle from April 2-7. Here’s a look at some of the highlights.
Biohaven Pharmaceutical Holding announced the acquisition of Channel Bio and new licensing rights to a spinal muscle atrophy drug from Bristol Myers Squibb.
The company said the study demonstrated broad efficacy, showing statistically significant superiority to placebo over a total of 15 prespecified primary and secondary outcome measures.
This week, Berkshire announced that it has scaled back those investments, and completely eliminated its stake in Merck.
Biohaven and Pfizer have partnered to market the Nurtec migraine medicine outside the U. S. once approved by global regulatory organizations. Here’s more about it.
Biohaven Pharma’s latest update on its Phase III clinical trial to use verdiperstat as a potential treatment for multiple system atrophy showed that it did not meet its expected outcomes.
A platform trial is also efficient in that it enables the investigators to share placebo information.
JOBS
IN THE PRESS